Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms Review


Authors: Mughal, T. I.; Pemmaraju, N.; Radich, J. P.; Deininger, M. W.; Kucine, N.; Kiladjian, J. J.; Bose, P.; Gotlib, J.; Valent, P.; Chen, C. C.; Barbui, T.; Rampal, R.; Verstovsek, S.; Koschmieder, S.; Saglio, G.; Van Etten, R. A.
Review Title: Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms
Abstract: The 60th American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13th Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on December 4 and 5, 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in the chronic MPNs to discuss the current scenario, including relevant presentations at ASH, and address pivotal open questions that impact translational research and clinical management. This review is based on the presentations and deliberations at this workshop, and rather than provide a resume of the proceedings, we have selected some of the important translational science and treatment issues that require clarity. We discuss the experimental and observational evidence to support the intimate interaction between aging, inflammation, and clonal evolution of MPNs, the clinical impact of the unfolding mutational landscape on the emerging targets and treatment of MPNs, new methods to detect clonal heterogeneity, the challenges in managing childhood and adolescent MPN, and reflect on the treatment of systemic mastocytosis (SM) following the licensing of midostaurin. © 2019 John Wiley & Sons, Ltd.
Keywords: myeloproliferative disorders; mutation; myeloproliferative disorder; united states; mouse; animal; animals; mice; congresses as topic; inflammation; chronic myeloid leukemia; oncology; societies, medical; medical society; organization; medical oncology; aging; dna mutational analysis; leukemia, myelogenous, chronic, bcr-abl positive; translational research; mastocytosis; midostaurin; procedures; staurosporine; translational medical research; humans; prognosis; human; clonal heterogeneity; ifnα; inflammaging; investigational therapies; mpns
Journal Title: Hematological Oncology
Volume: 37
Issue: 3
ISSN: 0278-0232
Publisher: Wiley Blackwell  
Date Published: 2019-08-01
Start Page: 240
End Page: 252
Language: English
DOI: 10.1002/hon.2622
PUBMED: 31013548
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 October 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Raajit Kumar Rampal
    338 Rampal